iBio, Inc. — Form 10-Q Summary
Business context and reporting period
iBio is a biotechnology company providing plant-based product development, contract development and manufacturing, technology-transfer services, and development of proprietary therapeutic candidates. This filing covers the quarter and six months ended December 31, 2018, the second quarter of fiscal 2019. The financial statements are unaudited and presented under U.S. GAAP.
Key financial metrics
| Metric | Three months ended Dec. 31, 2018 | Six months ended Dec. 31, 2018 |
|---|---|---|
| Revenue | $0.651 million | $0.696 million |
| Operating loss | $4.015 million | $7.965 million |
| Net loss attributable to iBio | $4.469 million | $8.867 million |
| Net loss available to common stockholders | $4.534 million | $8.998 million |
| Loss per share | $0.24 | $0.49 |
| Cash used in operating activities | Not separately provided | $5.448 million |
- Calculated operating margins were approximately negative 617% for the quarter and negative 1,144% for the six-month period. Net margins were approximately negative 697% and negative 1,293%, respectively.
- Cash was $13.361 million at December 31, 2018, compared with $15.934 million at June 30, 2018. Management stated that cash was expected to fund activities through at least November 30, 2019.
- Total assets were $40.303 million and total liabilities were $29.225 million. Current assets were $13.969 million versus current liabilities of $4.445 million.
- The principal financing obligation was a capital lease liability of $24.985 million, including $0.205 million current and $24.780 million long-term. The underlying Bryan, Texas facility sublease requires base rent of $2.1 million annually, subject to specified adjustments, plus percentage rent.
- Accumulated deficit was $97.095 million. Stockholders’ equity declined to $11.082 million from $16.166 million at June 30, 2018.
Material changes versus the prior comparable period
- Quarterly revenue increased $0.498 million, or approximately 325%, from $0.153 million; six-month revenue increased $0.421 million, or approximately 153%, from $0.275 million.
- The increase was primarily related to the CC-Pharming strategic relationship. The Company received approximately $2.9 million of prepayments during the quarter ended September 30, 2018 and recognized approximately $0.626 million as revenue during the quarter ended December 31, 2018. Approximately $2.526 million remained recorded as a contract liability at year-end.
- Quarterly operating expenses rose to $4.666 million from $3.580 million. Research and development increased to $1.273 million from $0.993 million, while general and administrative expense increased to $3.393 million from $2.587 million.
- Quarterly net loss attributable to iBio increased to $4.469 million from $3.899 million; six-month net loss increased to $8.867 million from $7.725 million.
- Operating cash use improved to $5.448 million for the six months from $6.605 million in the prior-year period, primarily because of the increase in contract liabilities.
- Financing activities provided $3.553 million, including $1.350 million of gross proceeds from the July 2018 sale of 1.5 million common shares and a $2.459 million working-capital contribution from an Eastern affiliate.
- Common shares outstanding increased to 18.837 million at December 31, 2018 from 16.040 million at June 30, 2018. A June 2018 public offering also included convertible preferred stock potentially convertible into approximately 13.4 million common shares in total, subject to applicable limitations and conversions.
Guidance, outlook, risks, contingencies, and unusual items
- Management expects continued significant expenses and operating losses and has not completed development or commercialization of any vaccine or therapeutic product candidate.
- The filing states that substantial doubt exists regarding the Company’s ability to continue as a going concern because of recurring losses, negative operating cash flow, limited cash resources, and dependence on additional financing. Management plans to use cash on hand, equity or other securities, collaboration and license proceeds, commercialization revenue, and iBio CDMO operations.
- If financing is unavailable, the Company may need to delay, reduce, or discontinue development and commercialization activities, accept less favorable collaborations, relinquish rights, or potentially cease operations. Additional equity financing could materially dilute stockholders.
- The Company’s lead proprietary candidate is IBIO-CFB03, an investigational therapy for fibrotic diseases, including systemic scleroderma and idiopathic pulmonary fibrosis. The filing provides no specific clinical or regulatory timing guidance.
- The Company received a $2.459 million related-party capital contribution from an Eastern affiliate in November 2018. Related-party expenses and obligations include capital-lease interest, facility-related costs, and services from affiliates and vendors.
- A $0.179 million fixed-asset write-off was recorded in the quarter. No intangible-asset impairment charges were recorded.
- The Company remains involved in litigation against Fraunhofer regarding alleged contractual breaches, technology ownership, and technology-transfer obligations. A separate complaint against Fraunhofer-Gesellschaft was dismissed as untimely on December 14, 2018; the action against Fraunhofer USA continued, and the outcome was not predictable.
- NYSE American listing deficiencies relating to share price and stockholders’ equity were reported during 2018. The Company stated that both deficiencies had been resolved by December 20, 2018.
- The Company adopted the new revenue-recognition standard effective July 1, 2018 without a significant financial statement impact. Adoption of other identified accounting standards also had no significant impact.
Important facts for investors to verify
- Whether CC-Pharming milestones and remaining contract liabilities convert into recognized revenue and cash as expected.
- The sustainability and commercial utilization of the iBio CDMO facility, given its substantial fixed lease obligations and continuing operating losses.
- The timing and terms of any required future financing, including potential equity dilution.
- The Company’s actual cash burn and liquidity beyond the stated November 30, 2019 expected runway.
- The potential dilution from Series A and Series B preferred stock and outstanding stock options.
- The status, possible financial impact, and intellectual-property implications of the Fraunhofer litigation.
- Progress toward regulatory development of IBIO-CFB03 and any future clinical or commercialization milestones.